osimertinib Archives - ILCN.org (ILCN/WCLC)

U.S. Drug Approvals: 2010 – 2020

on: April 16, 2020In: Evolving Standards of Care

Posted: April 16, 2020 Read more

Histologic Transformation From NSCLC to SCLC: A Mechanism of Resistance to Osimertinib and Other Agents Targeting EGFR Mutations

on: April 15, 2020In: Systemic, Targeted, & Immune Therapies

By Denis Moro-Sibilot, MD, MSc Posted: April 16, 2020 Dr. Denis Moro-Sibilot EGFR tyrosine kinase inhibitors (TKIs) are the standard of care for mutated EGFR NSCLC. Today, one of the […] Read more